Author
Listed:
- Byung-Je Sung
(CrystalGenomics, Inc., Daedeok Biocommunity)
- Kwang Yeon Hwang
(CrystalGenomics, Inc., Daedeok Biocommunity)
- Young Ho Jeon
(CrystalGenomics, Inc., Daedeok Biocommunity)
- Jae Il Lee
(CrystalGenomics, Inc., Daedeok Biocommunity)
- Yong-Seok Heo
(CrystalGenomics, Inc., Daedeok Biocommunity)
- Jin Hwan Kim
(CrystalGenomics, Inc., Daedeok Biocommunity)
- Jinho Moon
(CrystalGenomics, Inc., Daedeok Biocommunity)
- Jung Min Yoon
(CrystalGenomics, Inc., Daedeok Biocommunity)
- Young-Lan Hyun
(CrystalGenomics, Inc., Daedeok Biocommunity)
- Eunmi Kim
(CrystalGenomics, Inc., Daedeok Biocommunity)
- Sung Jin Eum
(CrystalGenomics, Inc., Daedeok Biocommunity)
- Sam-Yong Park
(Yokohama City University)
- Jie-Oh Lee
(Korea Advanced Institute of Science and Technology)
- Tae Gyu Lee
(CrystalGenomics, Inc., Daedeok Biocommunity)
- Seonggu Ro
(CrystalGenomics, Inc., Daedeok Biocommunity)
- Joong Myung Cho
(CrystalGenomics, Inc., Daedeok Biocommunity)
Abstract
Phosphodiesterases (PDEs) are a superfamily of enzymes that degrade the intracellular second messengers cyclic AMP and cyclic GMP1,2,3. As essential regulators of cyclic nucleotide signalling with diverse physiological functions, PDEs are drug targets for the treatment of various diseases, including heart failure, depression, asthma, inflammation and erectile dysfunction4,5,6,7. Of the 12 PDE gene families, cGMP-specific PDE5 carries out the principal cGMP-hydrolysing activity in human corpus cavernosum tissue. It is well known as the target of sildenafil citrate (Viagra) and other similar drugs for the treatment of erectile dysfunction. Despite the pressing need to develop selective PDE inhibitors as therapeutic drugs, only the cAMP-specific PDE4 structures are currently available8,9. Here we present the three-dimensional structures of the catalytic domain (residues 537–860) of human PDE5 complexed with the three drug molecules sildenafil, tadalafil (Cialis) and vardenafil (Levitra). These structures will provide opportunities to design potent and selective PDE inhibitors with improved pharmacological profiles.
Suggested Citation
Byung-Je Sung & Kwang Yeon Hwang & Young Ho Jeon & Jae Il Lee & Yong-Seok Heo & Jin Hwan Kim & Jinho Moon & Jung Min Yoon & Young-Lan Hyun & Eunmi Kim & Sung Jin Eum & Sam-Yong Park & Jie-Oh Lee & Tae, 2003.
"Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules,"
Nature, Nature, vol. 425(6953), pages 98-102, September.
Handle:
RePEc:nat:nature:v:425:y:2003:i:6953:d:10.1038_nature01914
DOI: 10.1038/nature01914
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:425:y:2003:i:6953:d:10.1038_nature01914. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.